Ovid Therapeutics (OVID) Stock Price, News & Analysis

Company Overview

Ovid Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for rare neurological disorders, including epilepsies and neurodevelopmental conditions. The company’s research programs are designed to address diseases with significant unmet medical needs and limited treatment options.

Ovid has developed a pipeline of investigational therapies targeting the underlying biology of neurological disorders. Its programs have included treatments for seizure disorders such as Dravet syndrome and Lennox-Gastaut syndrome, as well as potential therapies for other rare epileptic and neurodevelopmental conditions. The company does not have a broad portfolio of approved commercial products.

Founded in 2014, Ovid has advanced its programs through collaborations with pharmaceutical companies, including a development partnership with Takeda Pharmaceutical Company involving soticlestat. Its clinical development activities have involved patients and research sites in the United States and other international markets. Ovid is headquartered in New York.

Key Stats

• Today's Range: $2.29 to $2.47
• 50-Day Range: $2.22 to $2.93
• 52-Week Range: $1.18 to $3.11
• Volume: 1.19 million shs
• Average Volume: 1.71 million shs
• Market Capitalization: $457.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.13
• Consensus Rating: Moderate Buy

Ovid Therapeutics Stock Analysis - MarketRank™

Ovid Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 704th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ovid Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 1 strong buy rating, 9 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Ovid Therapeutics has a consensus price target of $6.13, representing about 161.8% upside from its current price of $2.34.

Amount of Analyst Coverage

Ovid Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Ovid Therapeutics are expected to decrease in the coming year, from ($0.37) to ($0.39) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ovid Therapeutics is -7.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ovid Therapeutics is -7.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ovid Therapeutics has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.65% of the float of Ovid Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Ovid Therapeutics has a short interest ratio ("days to cover") of 17.25, which indicates bearish sentiment.

Change versus previous month

Short interest in Ovid Therapeutics has recently increased by 2.30%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ovid Therapeutics does not currently pay a dividend.

Dividend Growth

Ovid Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Ovid Therapeutics this week, compared to 3 articles on an average week.

MarketBeat Follows

6 people have added Ovid Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ovid Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.00% of the stock of Ovid Therapeutics is held by insiders.

Percentage Held by Institutions

72.24% of the stock of Ovid Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:OVID
• CIK: 1636651
• Web: www.ovidrx.com
• Phone: (646) 661-7661
• Fax: N/A
• Employees: 23
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Ovid Therapeutics: $6.13
• High Price Target: $9.00
• Low Price Target: $4.00
• Potential Upside/Downside: +161.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.41 million
• Net Margins: N/A
• Pretax Margin: -2,178.90%
• Return on Equity: -23.64%
• Return on Assets: -20.52%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 12.39
• Quick Ratio: 12.39

Sales & Book Value

• Annual Sales: $1.58 million
• Price / Sales: 288.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.00 per share
• Price / Book: 2.34

Miscellaneous

• Outstanding Shares: 195,298,000
• Free Float: 181,627,000
• Market Cap: $457.00 million
• Optionable: Optionable
• Beta: 0.22